Defeat Duchenne Canada, the country's leading funder of Duchenne muscular dystrophy (DMD) research, is set to begin accepting innovative research proposals as of March 31, 2025. They are seeking ...

Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with ...

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

When William's 10th birthday approached, Conde reached out to Little Treasures, the pediatric program for Treasure Coast ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Shares of PTC Therapeutics fell after the company said regulators for the European Union won't renew authorization for its Translarna treatment for nonsense mutation Duchenne muscular dystrophy.

Officials at ARM, ASGCT, and ISCT convened a small group of scientists, policy experts, religious leaders and patient ...

Previous studies have shown that protein expression of DOCK7 is increased in skeletal muscle biopsies from patients with Duchenne muscular dystrophy (DMD), leading researchers from the University of ...

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.